The Lynx Group

Web Exclusives

Web Exclusives — May 18, 2020
On May 15, 2020, the FDA approved a new indication for the first immunotherapy combination with the PD-1 inhibitor nivolumab (Opdivo; BMS) and the CTLA-4 inhibitor ipilimumab (Yervoy; BMS) as first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and PD-L1 expression of ≥1%, as determined by an FDA-approved test, but without EGFR or ALK genomic alterations.
Read Article

Web Exclusives — May 5, 2020
On May 1, 2020, the FDA approved a new formulation of daratumumab (Darzalex; Janssen Biotech) and hyaluronidase-fihj (Faspro; Janssen Biotech) for the treatment of adults with newly diagnosed or with relapsed or refractory multiple myeloma. This new formulation allows for the subcutaneous administration of daratumumab as an alternative to its intravenous (IV) administration. The new formulation is approved for the indications previously approved for IV daratumumab.
Read Article

Web Exclusives — May 5, 2020
As a result of the ongoing COVID-19 pandemic, comprehensive cancer care centers have been tasked with significantly altering their strategies for the delivery of care. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discuss some of the changes that have already been implemented at their centers and future considerations for healthcare systems as they focus on providing safe and effective care on the road to recovery.
Read Article

Web Exclusives — May 5, 2020
Issues surrounding healthcare insurance continue to unfold in light of the recent COVID-19 pandemic. In this discussion, a panel of managed care experts, moderated by Michael Kolodziej, MD, explore strategies for reducing the total cost of care for patients with cancer and addressing the economic and administrative burdens that practices and payers are facing as a result of the crisis.
Read Article

Web Exclusives — May 5, 2020
Addressing the significant physical and psychosocial needs of patients with cancer during the COVID-19 crisis remains a top priority for healthcare providers. In this discussion, moderated by Elizabeth Franklin, PhD, MSW, a panel of specialists explore efforts underway to advocate for patients who are coping with stress, anxiety, and various economic burdens.
Read Article

Web Exclusives — May 4, 2020
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Read Article

Web Exclusives — May 4, 2020
On April 28, 2020, the FDA accelerated the approval of a new dosing regimen—400 mg every 6 weeks—for pembrolizumab (Keytruda; Merck) for all the 15 indications currently approved by the FDA for adults using this PD-1 inhibitor. The new dosing regimen is a new option in addition to the current dosing regimen of 200 mg every 3 weeks. This is great news for patients, as well as for oncology providers.
Read Article

Web Exclusives — April 28, 2020

In the Association for Value-Based Cancer Care (AVBCC) webcast, titled Wholesale Supply Channels: COVID-19 Impact on Cancer Care and Road to Recovery, a panel of healthcare experts discussed issues related to wholesale supply channels for the distribution of drugs and medical/surgical supplies to community oncology care providers.

Read Article

Web Exclusives — April 17, 2020
Cranbury, NJ – Fueled by the success of its live webcast earlier this month, the Association for Value-Based Cancer Care (AVBCC) is launching a free webinar series titled COVID-19 Impact on the Cancer Care Delivery Ecosystem.
Read Article

Web Exclusives — March 19, 2020
The Centers for Medicare & Medicaid Services (CMS) has broadened access to Medicare telehealth services so that beneficiaries can receive a wider range of services from their physicians without having to travel to a healthcare facility. Clinicians can bill immediately for services starting March 6, 2020.
Read Article

Page 2 of 9

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: